21.83 USD
▼-0.37-1.67%
盘后 20.51 -6.05%
2026-09-15
市值
$2.54B
市盈率
—
EPS
-3.46
股息率
—
52 周区间
13.18 – 34.29
成交量
1.21M
Beta
0.96
目标价
36.63
52W 低 13.1852W 高 34.29
价格走势
公司简介
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves’ disease and TED. Its portfolio of engineered inhibitors o...